Published in final edited form as:

Pediatr Infect Dis J. 2016 November ; 35(11): 1182–1186. doi:10.1097/INF.0000000000001286.

Inherent Risk Factors for Nosocomial Infection in the Long Stay Critically Ill Child Without Known Baseline Immunocompromise: A Post –Hoc Analysis of the CRISIS Trial

Joseph A Carcillo, MD¹, J Michael Dean, MD², Richard Holubkov, PhD², John Berger, MD³, Kathleen L Meert, MD⁴, KJS Anand, MD⁵, Jerry Zimmerman, MD⁶, Christopher J Newth, MD⁷, Rick Harrison, MD⁸, Jeri Burr, RN², Douglas F. Willson, MD⁹, Carol Nicholson, MD¹⁰, Michael J. Bell, MD¹, Robert A. Berg, MD¹¹, Thomas P. Shanley, MD¹², Sabrina M Heidemann, MD⁴, Heidi Dalton, MD¹³, Tammara L. Jenkins, RN¹⁰, Allan Doctor, MD¹⁴, Angie Webster, MStat², and on behalf of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Collaborative Pediatric Critical Care Research Network (CPCCRN)

¹ Department of Critical Care Medicine and Pediatrics University of Pittsburgh

² Department of Pediatrics University of Utah

³ Department of Pediatrics George Washington University

⁴ Department of Pediatrics Wayne State University

⁵ Department of Pediatrics University of Arkansas

⁶ Department of Pediatrics University of Washington

⁷ Department of Pediatrics University of Southern California

⁸ Department of Pediatrics University of California at Los Angeles

⁹ Department of Pediatrics University of Virginia

¹⁰ Eunice Kennedy Shriver National Institutes of Child Health and Development

¹¹ Department of Pediatrics University of Pennsylvania

¹² Department of Pediatrics University of Michigan

¹³ Department of Pediatrics University of Arizona

¹⁴ Department of Pediatrics, Washington University at St. Louis, St. Louis, Missouri.

Abstract

Background—Nosocomial infection remains an important health problem in long stay (> 3 days) pediatric intensive care unit (PICU) patients. Admission risk factors related to the development of nosocomial infection in long stay immune competent patients in particular are not known.

Corresponding Author Joseph A. Carcillo, M.D.; Suite 2000, Faculty Pavilion, Children's Hospital of Pittsburgh, 4400 Penn Avenue, Pittsburgh PA 15214; Fax number 412-692-6076; Telephone number 412-420-5054; carcilloja@ccm.upmc.edu.

Methods—Post-hoc analysis of the previously published Critical Illness Stress induced Immune Suppression (CRISIS) prevention trial database, to identify baseline risk factors for nosocomial infection. Because there was no difference between treatment arms of that study in nosocomial infection in the population without known baseline immunocompromise, both arms were combined and the cohort that developed nosocomial infection was compared with the cohort that did not.

Results—There were 254 long stay PICU patients without known baseline immunocompromise. Ninety (35%) developed nosocomial infection, and 164 (65%) did not. Admission characteristics associated with increased nosocomial infection risk were increased age, higher PRISM III score, the diagnoses of trauma or cardiac arrest, and lymphopenia ($p < 0.05$). The presence of sepsis or infection at admission was associated with reduced risk of developing nosocomial infection ($p < 0.05$). In multivariable analysis, only increasing age, cardiac arrest, and existing lymphopenia remained significant admission risk factors ($p < 0.05$); whereas trauma tended to be related to nosocomial infection development ($p = 0.07$).

Conclusions—These data suggest that increasing age, cardiac arrest, and lymphopenia predispose long stay PICU patients without known baseline immunocompromise to nosocomial infection. These findings may inform pre-hoc stratification randomization strategies for prospective studies designed to prevent nosocomial infection in this population.

Keywords

Nosocomial infection; pediatric intensive care unit; immune competent host

Introduction

Despite widespread implementation of *Centers for Disease Control* recommendations, including hand washing and infection prevention bundles, hospital acquired nosocomial infection remains an important problem in critically ill children.¹ It is well established that hospital acquired infections are more common in long stay patients who are in the pediatric intensive care unit (PICU) for longer than three days with concomitant invasive measures.^{2,3} Up to 40% of these children acquire nosocomial infection and/or sepsis after being in the pediatric intensive care unit for 14 days. Among this population, children with known immunocompromise at baseline are at greatest risk for acquiring nosocomial infection related in part to their inability to fight infection; however, this group of children accounts for at most 10 % of the population in the pediatric intensive care unit.³ An important knowledge gap exists as to what factors predispose to, or protect against development of nosocomial infection in the other 90% of long stay pediatric intensive care unit patients without known baseline immunocompromise.

Many randomized interventional nutritional studies have been performed to determine whether nutraceuticals can prevent nosocomial infections in critically ill premature neonates, children, and adults. In this regard, we completed the Critical Illness Stress induced Immune Suppression (CRISIS) prevention comparative effectiveness trial in which long stay pediatric intensive care patients were stratified according to baseline immune status and randomized to one of two nutraceutical strategies: whey protein with essential amino acids and

lactoferrin, or zinc, selenium, glutamine, and the prolactin secretagogue metoclopramide.³ There were no differences in time to nosocomial infection or rate of nosocomial infection between treatment arms in the population without known immunocompromise at baseline. In order to identify risk factors for the development of nosocomial infection and to inform future interventional trials in long stay pediatric intensive care unit patients without known baseline immunocompromise, we performed a retrospective cohort analysis of this trial's database comparing patients in this group who did and did not develop nosocomial infection.

Methods

Patients were recruited from and enrolled in the pediatric intensive care units of eight centers in the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. These sites included Arkansas Children's Hospital, Children's Hospital of Los Angeles, Mattel Children's Hospital of UCLA, Seattle Children's Hospital and Harborview, Children's Hospital of Michigan in Detroit, Children's National Medical Center in Washington DC, and Children's Hospital of Pittsburgh. Entry criteria in the randomized trial were an expected stay greater than three days with indwelling invasive devices including mechanical ventilation, central venous catheters, and indwelling urinary catheters, and age > 1 year but < 18 years. Exclusion criteria included the following; 1) had a known allergy to metoclopramide; 2) were expected to have planned removal of endotracheal tube, central venous, and urinary catheters, within 72 hours after study enrollment, 3) had suspected intestinal obstruction, 4) had intestinal surgery or bowel disruption, 5) had other contraindications to the enteral administration of drugs or nutrients, 6) received chronic metoclopramide therapy prior to enrollment, 7) had a known allergy to whey (cow's milk) or soy based products, 8) had been discharged from the PICU in the previous 28 days, 9) had been previously enrolled in this study, or 10) had a positive pregnancy test. Patients were also excluded if their parents indicated a lack of commitment to aggressive intensive care therapies.

In this exploratory analysis, long pediatric intensive care unit stay is defined as more than 3 days in the PICU. Therefore, we included all pediatric intensive care unit patients who were not known to have baseline immunocompromise, and who were followed for more than 3 days after PICU admission in our previously published randomized, double-blinded, comparative effectiveness trial for the prevention of Critical Illness Stress induced Immune Suppression related nosocomial infection.³ Children were considered to have no known baseline immunocompromise if they were not found to have an admission diagnosis of cancer, Acquired Immune Deficiency Syndrome, solid organ transplantation, stem cell transplantation, autoimmune disease, primary immunodeficiency syndromes, or chronic use of immune suppressant therapies. In this analysis, patient study records were reviewed in detail for these characteristics, and thus numbers differ slightly from the previously reported "as-randomized" immune competent stratum (3). Specifically, 266 of the 293 enrolled children were considered to have no known baseline immunocompromise in this review, with 254 meeting the long PICU stay criterion and therefore analyzed in this report.

Nosocomial infection was defined according to *Centers for Disease Control* criteria. Infection was defined by a positive culture, polymerase chain reaction assay, or antigen test

identifying an organism in a patient with fever, systolic blood pressure < 90 mm/hg, or urine output < 20 mL / hour considered to be the cause of these symptoms for which the primary clinician chose to treat the patient with anti-microbial therapy if available. Nosocomial infections were identified by the site principal investigators and clinical research coordinators. All identified nosocomial infections were then adjudicated by the network steering committee which included the site principal investigators, representatives of the data coordinating center (University of Utah) and the network scientific research officer (National Institutes of Child Health and Development). Nosocomial infection events were defined as occurring at least 48 hours after pediatric intensive care unit admission during the hospital stay until 5 days after discharge from the pediatric intensive care unit. For children remaining in the pediatric intensive care unit for >28 days, events were counted for up to 33 days.

As this trial showed no difference in the time to development of or rate of nosocomial infection between treatment arms (beneprotein vs zinc, selenium, glutamine and metoclopramide) we included both treatment arms of the study in our *post hoc* analysis of the population without known baseline immunocompromise. For these analyses, the patients were grouped into two cohorts those who developed nosocomial infection, and those who did not. Baseline characteristics were compared in order to evaluate the role of inherent pre-existing risk factors.

Three scoring systems were used to assess severity of illness as a risk factor for later development of nosocomial infection. The Pediatric Logistic Organ Dysfunction (PELOD) score, an organ dysfunction severity scale designed to predict population mortality risk in the PICU, was collected on Study Day 1.⁴ The Pediatric Risk of Mortality version III (PRISM III) score, a physiologic function scale designed to predict population mortality risk in the PICU, was collected in the first 12 hours of PICU admission.⁵ The Organ Failure Index (OFI), an organ failure scale designed to count the number of organ failures, was collected on Study Day 1.⁶ Study Day 1 was defined as the first day study drug administration was attempted and it varied from 0 to 3 days following PICU admission (median = 2 days following PICU admission).

Existing lymphopenia was defined as an absolute lymphocyte count $\leq 1,000 / \text{mm}^3$ from PICU admission until the first study treatment (median = 2 days following PICU admission). Existing neutropenia was defined as an absolute neutrophil count $\leq 1,000 / \text{mm}^3$ from PICU admission until the first study treatment (median = 2 days following PICU admission).

Statistical Analyses

We compared pediatric intensive care unit admission characteristics between the two cohorts. Categorical variables are summarized as absolute counts and percentages. Continuous variables are summarized as means, standard deviations, medians and ranges. The statistical significance of association between the development of nosocomial infection and each characteristic was assessed by the Pearson chi-square test or Fisher's exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. Reported significance levels are not adjusted for multiple comparisons as this analysis is considered exploratory.

Multivariable logistic regression was also used to evaluate the potential association between pediatric intensive care unit admission characteristics and the development of nosocomial infection. Multivariable analyses were restricted to those with available lymphopenia data (208 of 254 patients). Variables with $p < 0.1$ in univariable analysis were considered for inclusion in the logistic regression model. The final model was determined using stepwise selection, with significance level of 0.1 for entry and 0.1 to remain in the model. Adjusted odds ratios with 95% confidence intervals and significance level from the Wald chi-square test are provided for each variable in the final model.

Results

Two hundred and fifty four long stay pediatric intensive care unit patients were identified in the database to have no known baseline immunocompromise. Ninety (35%) subsequently developed nosocomial infection whereas 164 (65%) did not develop nosocomial infection. The number of days in the pediatric intensive care unit at the time of developing nosocomial infection was a mean of 8.5 with a standard deviation of 5.3.

The entire pediatric intensive care unit stay was longer in the children who developed nosocomial infection (mean 23.4 days; standard deviation 19.6 days) compared to those who did not (mean 10.0 days; standard deviation 8.1 days). There were 146 total nosocomial infections and co-infections with 40% of the patients with nosocomial infection ($n = 36$) having multiple infections. By far the respiratory tract was the most common site of nosocomial infection ($n = 92$ lower tract; $n = 3$ upper tract), with urinary tract ($n = 17$), skin soft tissue ($n = 12$), and blood stream ($n = 16$) being similar at less than 20% of the incidence of the respiratory tract. Six patients had other sites of nosocomial infection. Table 1 shows the nosocomial infection and co-infection species identifications. There were a total of 197 infecting organisms with 35 fungi, 80 gram negative bacilli, 2 gram-positive bacilli, 4 gram negative cocci, 67 gram positive cocci, 5 viruses, and 4 undetermined. Most infections were consistent with a hospital acquired organism ecology rather than a community acquired organism ecology with only 13 being *haemophilus influenza*, 1 being *haemophilus parainfluenza*, and 4 being *moraxella catarrhalis*.

Table 2 shows the admission and baseline characteristics of the cohorts of children who did and did not develop nosocomial infection. Because only three patients had baseline neutropenia, this characteristic was not assessed in statistical analysis. In univariable analysis, increased age in years, increased severity of illness as indicated by higher Pediatric Risk of Mortality (PRISM) III score, the primary or secondary diagnosis of Cardiac Arrest or Trauma, and the presence of lymphopenia ($\leq 1,000 /\text{mm}^3$) were all associated with the development of nosocomial infection ($p < 0.05$). Severity of illness measured by the Pediatric Logistic Organ Dysfunction (PELOD) score tended to be associated with increased risk ($p = 0.09$). By contrast the presence of infection or sepsis at admission was associated with protection against the subsequent development of nosocomial infection ($p < 0.05$).

Table 3 shows the final multivariable model of factors independently associated with development of nosocomial infection. In this model, increasing age, cardiac arrest, and lymphopenia continued to be significant risk factors ($p < 0.05$) whereas trauma tended to be

a risk factor ($p = 0.07$) for development of nosocomial infection. Among these, the greatest risk was associated with cardiac arrest (adjusted odds ratio of 6.7 and a 95% confidence interval of 1.6-28.1). The most prevalent risk factor was lymphopenia, which was present in 78 / 208 (38%) of patients without known baseline immunocompromise (adjusted odds ratio of 2.0 and 95% confidence interval of 1.1 to 3.8). Ten patients developed lymphopenia ≥ 7 days of whom 5 developed nosocomial infection (50%) compared to the 78 patients with baseline lymphopenia of whom 37 developed nosocomial infection (47%). For every ten years of age the odds of developing nosocomial infection nearly doubles (for a child one year older than another, the estimated odds ratio was 1.06 with 95% confidence interval of 1.01-1.12).

Discussion

To our knowledge this cohort analysis is the first study to ask the question whether there are inherent clinical factors which are associated with an increase or decrease in the risk of developing nosocomial infection in the long stay pediatric intensive care unit population that does not have known baseline immunocompromise. Studies have previously shown that long stay pediatric intensive care unit patients have increased rates of hospital acquired infections compared to short stay patients, with a 40% incidence of nosocomial infection observed by 14 days.¹⁻³ Our present cohort analysis represents the first study to evaluate what inherent characteristics determine risk among long stay critically ill children without known baseline immunocompromise. In this regard we have attained several previously unappreciated insights. Primary or secondary admission diagnoses of cardiac arrest or trauma were associated with or tended to be associated with the development of nosocomial infection, and the presence of lymphopenia or increasing age further increased this risk. These findings inform future clinical investigations of nosocomial infection prevention strategies in critically ill children without known baseline immunocompromise.

The occurrence of nosocomial infections in children without known baseline immunocompromise in the Critical Illness Stress induced Immune Suppression prevention trial was common, happening in over a third of the children. Multiple episodes of nosocomial infection, and co-infections were not uncommon. The organisms identified were for the most part characteristic of hospital acquired ecology. Children who developed nosocomial infections were on average in the pediatric intensive care for 8.5 days before infection onset. On average, their time in the pediatric intensive care unit was increased out nearly two weeks compared with children who did not develop nosocomial infection, who on average had a length of stay just over one week.

Cardiac arrest was associated with six fold increased odds of developing nosocomial infections. This is biologically plausible for several reasons. First, regurgitation and aspiration pneumonia occur commonly among adults successfully resuscitated from cardiac arrest and might also occur in children.⁷⁻⁹ Second, cardiac arrest may impair bowel wall barrier integrity as a result of ischemia-reperfusion injury leading to bacterial translocation and nosocomial infection. Third, cardiac arrest survivors usually need continued invasive mechanical ventilation and hemodynamic monitoring with arterial and venous catheters that increase their risk for hospital acquired infections. The very high risk of nosocomial

infections among these critically ill children post cardiac arrest indicates that this group deserves special attention for monitoring and prompt treatment. Trauma tended to increase nosocomial infection risk. This is also biologically plausible because trauma and tissue injury destroys physical barrier defenses against bacterial and fungal infection. Skin lacerations allow for direct infection with skin and soil flora.¹⁰⁻¹³ Lymphopenia was the most common risk factor in the development of nosocomial infection as it occurred in one third of the children with available data. Lymphopenia is a recognized risk factor for the development of nosocomial infection in trauma and surgery patients.¹⁴⁻¹⁶ This may be related to a heightened stress response leading to lymphocyte apoptosis and impaired immune function.^{17, 18} Felmet et al previously reported increased risk of nosocomial infection in critically ill children when lymphopenia persisted beyond seven days.¹⁸ In our present study we observed that the incidence of developing nosocomial sepsis in patients with baseline lymphopenia was similar to the incidence we observed in patients with prolonged lymphopenia. The mechanism by which increasing age might increase proclivity to nosocomial infection is not known although some have suggested that pre-existing or ICU acquired dental and gingival biofilms can predispose to nosocomial pneumonia with age.¹⁹

The protective effect of having infection or sepsis at admission on subsequent development of nosocomial infections fell out in multivariable analysis. It appears paradoxical in the univariable analysis because severe sepsis is known to induce a secondary immune suppression period in approximately one-third of hosts who have sepsis induced multiple organ failure syndrome.^{18, 20, 21} It is possible that the treatment of all patients who had infection or sepsis at admission with antibiotics prevented the onset of nosocomial infection through an unintended antibiotic 'prophylaxis' effect. The harmful effects of increased severity of illness as measured by the PRISM III and PELOD also fell out in multivariable analysis.

There are several important limitations to consider in evaluating our study. First, we used the Centers for Disease Control (CDC) pediatric criteria for diagnosing nosocomial infection at the time that this comparative effectiveness study was performed. We did this because we considered the CDC to be an authority on definitions of hospital acquired infection in children; however, there is not consensus among pediatric critical care infectious disease experts regarding these CDC criteria. This lack of a true gold standard for diagnosing infection in this population makes it quite possible that the sensitivity and specificity of our findings are negatively affected by over-estimation of true infection incidence. Second, ten years have passed since beginning the CRISIS study and subsequent implementation of national and international initiatives using care bundles to reduce nosocomial infection from central lines, ventilators, and urinary catheters. This also supports the likelihood that our nosocomial infection incidence represents an overestimate compared with today's true nosocomial infection incidence. Third, the patient population sample in this study received either daily enteral whey protein, or daily enteral zinc, selenium, and glutamine and intravenous metoclopramide as part of a comparative effectiveness trial. Because neither treatment arm affected the time to development or the rate of nosocomial infection in our population of interest, we grouped them together for the purposes of this exploratory analysis. Although this may seem reasonable, patients who agree to be part of a randomized interventional trial may be different from other long stay pediatric intensive care unit

patients in ways we do not know. A fourth limitation is that the clinical characteristics evaluated were designed for the purposes of the comparative effectiveness trial, not for the purpose of this cohort analysis. The small sample size attained in the randomized interventional trial also provides the possibility of a Type II error. These limitations could be overcome by looking at larger databases; however, our purpose in doing this post-hoc analysis was to inform planning of future trials of nutraceuticals to prevent nosocomial infection in the long stay pediatric intensive care unit patient without known baseline immunocompromise. For our purposes these limitations can be viewed as strengths, because the type of patients and families who agreed to enrollment and the data collected in future interventional trial efforts will likely be similar to the patient population enrolled and data collected in the CRISIS prevention comparative effectiveness trial.

In future interventional nutraceutical trials designed to prevent nosocomial infection in hosts without known baseline immunocompromise, investigators can be informed by the findings observed in this post-hoc analysis. Increasing age, cardiac arrest, and lymphopenia predispose to nosocomial infection, whereas children with trauma have an increased tendency towards nosocomial infection. Consideration can be given to stratified randomization according to the presence or absence of lymphopenia because fully one-third of subjects will be expected to be lymphopenic with a 2- fold increased odds of developing infection. Consideration can also be given to excluding cardiac arrest patients because they have more than a 6 fold increased odds and represent only 5% of the population. Increasing age can be adjusted for using an *a priori* analytical strategy. The trauma populations can be evaluated separately or similarly adjusted for using an *a priori* analytical strategy. Future interventional trials aimed at reducing nosocomial infection risk in long stay pediatric intensive care unit patients without known baseline immunocompromise should consider strategies controlling for these risk factors.

Acknowledgments

Conflicts of Interest and Source of Funding

Angie Webster consulted with Pentara Corporation (statistical consultancy). There are no other conflicts of interest to report other than that this work was supported by the following cooperative agreements from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Department of Health and Human Services (DHHS): U10HD050096, U10HD049981, U10HD050009, U10HD049945, U10HD049983, U10HD050012, U10HD063106, U10HD063108, U10HD063114 and U01HD049934.

References

1. Gravel D, Matlow A, Ofner-Agostini M, et al. A point prevalence survey of health care associated infections in pediatric population in major Canadian acute care hospitals. *Am J Infect Control*. 2007; 35:157–162. [PubMed: 17433938]
2. LeClerc F, Leteurtre S, Duhamel A, et al. Cumulative influence of organ dysfunctions and septic state on mortality of critically ill children. *Am J Respir Crit Care Med*. 2005; 171:348–353. [PubMed: 15516535]
3. Carcillo JA, Dean JM, Holubkov R, et al. The randomized comparative pediatric critical illness stress-induced immune suppression (CRISIS) prevention trial. *Pediatr Crit Care Med*. 2012; 13:165–173. [PubMed: 22079954]

4. Leteurtre S, Martinot A, Duhamel A, Gauvin F, Grandbastien B, Nam TV, Proulx F, Lacroix J, Leclerc F. Development of a pediatric multiple organ dysfunction score: use of two strategies. *Med Decis Making*. 1999; 19(4):399–410. [PubMed: 10520678]
5. Pollack MM, Patel KM, Ruttimann UE. The Pediatric Risk of Mortality III--Acute Physiology Score (PRISM III-APS): a method of assessing physiologic instability for pediatric intensive care unit patients. *J Pediatr*. 1997; 131(4):575–81. [PubMed: 9386662]
6. Doughty LA, Kaplan SS, Carcillo JA. Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. *Crit Care Med*. 1996; 24(7):1137–43. [PubMed: 8674325]
7. Virkkunen I, Ryyänen S, Kujala S, Vuori A, Piilonen A, Kääriä JP, Kähärä V, Pettilä V, Yli-Hankala A, Silfvast T. Incidence of regurgitation and pulmonary aspiration of gastric contents in survivors from out-of-hospital cardiac arrest. *Acta Anaesthesiol Scand*. Feb; 2007 51(2):202–5. [PubMed: 17261147]
8. Tsai MS, Chiang WC, Lee CC, Hsieh CC, Ko PC, Hsu CY, Su CP, Chen SY, Chang WT, Yuan A, Ma MH, Chen SC, Chen WJ. Infections in the survivors of out-of-hospital cardiac arrest in the first 7 days. *Intensive Care Med*. 2005; 31(5):621–6. Epub 2005 Apr 1. [PubMed: 15803297]
9. Gajic O, Festic E, Afessa B. Infectious complications in survivors of cardiac arrest admitted to the medical intensive care unit. *Resuscitation*. 2004; 60(1):65–9. [PubMed: 14987786]
10. Taira BR, Fenton KE, Lee TK, et al. Ventilator associated pneumonia in pediatric trauma patients. *Pediatr Crit Care Med*. 2009; 10:491–494. [PubMed: 19451852]
11. Upperman JS, Sheridan R. Pediatric susceptibility to sepsis. *Pediatr Crit Care Med*. 2005; 6(3 Suppl):S108–111. [PubMed: 15857542]
12. Urrea M, Torner F, Pons M, Latorre C, Huguet R. Incidence study of nosocomial infection in pediatric trauma patients. *J Pediatr Orthop B*. 2005; 14:371–374. [PubMed: 16093950]
13. Brook I. Infectious complications following trauma in children. *Adv Pediatr*. 1997; 44:429–451. [PubMed: 9265978]
14. Meert KL, Ofenstein JP, Sarnaik AP. Altered T cell cytokine production following mechanical trauma. *Ann Clin Lab Sci*. 1998; 28:283–288. [PubMed: 9784829]
15. Meert KL, Long M, Kaplan J, Sarnaik AP. Alterations in immune function following head injury in children. *Crit Care Med*. 1995; 23:822–828. [PubMed: 7736738]
16. Heffernan DS, Monaghan SF, Thakkar RK, Machan JT, Cioffi WG, Ayala A. Failure to normalize lymphopenia following trauma is associated with increased mortality independent of leukocytosis pattern. *Crit Care*. 2012; 16:R12. syndrome. *Intensive*. [PubMed: 22264310]
17. Lucin KM, Sanders VM, Popovich PG. Stress hormones collaborate to induce lymphocyte apoptosis after high spinal cord injury. *J Neurochem*. 2009; 110:1409–1421. [PubMed: 19545280]
18. Felmet KA 1, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. *J Immunol*. 2005; 174(6):3765–72. [PubMed: 15749917]
19. Shi Z 1, Xie H, Wang P, Zhang Q, Wu Y, Chen E, Ng L, Worthington HV, Needleman I, Furness S. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. *Cochrane Database Syst Rev*. 2013; 8:CD008367.
20. Hall MW, Knatz NL, Vetterly C, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. *Intensive Care Med*. 2011; 37:525–532. [PubMed: 21153402]
21. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. *Shock*. 2014; 42(5):383–91. [PubMed: 25051284]

Table 1

Nosocomial infection identification

Total Number of Infecting Organisms	N=197
Fungi	35
<i>candida albicans</i>	9
<i>candida tropicalis</i>	6
Yeast	7
<i>candida glabrata</i>	4
<i>candida lusitanae</i>	4
Other fungi <i>aspergillus niger</i> (2), <i>candida</i> (1), <i>candida parapsilosis</i> (1), <i>cryptococcus</i> (1)	5
Gram Negative Bacilli	80
<i>pseudomonas aeruginosa</i>	27
<i>haemophilus influenzae</i>	13
<i>stenotrophomonas maltophilia</i>	7
<i>enterobacter cloacae</i>	6
<i>klebsiella pneumoniae</i>	6
Other Gram Negative Bacilli - <i>serratia marscescen</i> (4), <i>acinetobacter baumannii</i> (3), <i>citrobacter freundii</i> (3), <i>escherichia coli</i> (3), <i>klebsiella oxytoca</i> (2), <i>haemophilus parainfluenza</i> (1), <i>enterobacter aerogenes</i> (1), <i>eikenella</i> species (1), <i>acinetobacter</i> species (1), <i>pantoea agglomerans</i> (1), <i>enterobacter</i> species (1)	21
Gram Positive Bacilli	2
<i>Clostridium difficile</i>	2
Gram Negative Cocci	4
<i>moraxella catarrhalis</i>	4
Gram-Positive Cocci	67
<i>staphylococcus aureus</i>	31
<i>staphylococcus</i> coagulase negative	9
<i>enterococcus faecalis</i>	4
<i>staphylococcus epidermidis</i>	4
Other Gram –Positive Cocci - <i>enterococcus</i> species (3), methicillin resistant <i>staphylococcus aureus</i> (3), <i>viridans streptococci</i> (2), <i>streptococcus pneumoniae</i> (2), vancomycin resistant <i>enterococcus faecium</i> (1), <i>enterococcus raffinosus</i> (1), <i>enterococcus aerogenes</i> (1), <i>enterococcus cloacae</i> (1), <i>staphylococcus</i> (1), <i>streptococcus</i> species (1), <i>micrococcus</i> species (1), <i>streptococcus viridans</i> group 2 (1), <i>streptococcus</i> serogroup F (1)	19
Virus	5
Undetermined	4

Table 2

Admission factors in patients who did and did not develop nosocomial infection

	No Nosocomial Infection N = 164	Nosocomial Infection N = 90	p-value
Age (years)			
Min, Max	1, 17.9	1, 17.9	
Mean (SD)	7.4 (5.5)	9.2 (5.8)	
Median (Q1, Q3)	5.1 (2.1, 12.6)	8.7 (3.6, 15.1)	0.01
Female	80 (49%)	48 (53%)	0.49
PELOD score			
Min, Max	0, 50	0, 41	
Mean (SD)	9.8 (7.8)	12.2 (10.2)	
Median (Q1, Q3)	11 (2, 12)	11 (2, 21)	0.09
PRISM III score			
Min, Max	0, 28	0, 34	
Mean (SD)	8.2 (6.3)	10 (6.8)	
Median (Q1, Q3)	7 (3, 12)	8 (5, 13)	0.04
OFI score			
Min, Max	0, 5	0, 6	
Mean (SD)	1.7 (1)	1.8 (1.1)	
Median (Q1, Q3)	2 (1, 2)	2 (1, 3)	0.24
Post-operative	45 (27%)	28 (31%)	0.54
Infection or sepsis	113 (69%)	49 (54%)	0.02
Lymphopenia (ALC <= 1,000 mm ³)	41 (31%) [N = 134]	37 (50%) [N = 74]	0.01
Primary or Secondary Diagnosis			
Asthma	8 (5%)	2 (2%)	0.50
Cardiac arrest	4 (2%)	9 (10%)	0.01
Cardiovascular disease acquired	1 (1%)	3 (3%)	0.13
Cardiovascular disease congenital	13 (8%)	4 (4%)	0.29
Chromosomal abnormality	2 (1%)	3 (3%)	0.35
Diabetes	1 (1%)	0 (0%)	1.00
Drug overdose	2 (1%)	0 (0%)	0.54
Hypoxic ischemic encephalopathy	3 (2%)	0 (0%)	0.55
Meningitis	4 (2%)	2 (2%)	1.00

	No Nosocomial Infection N = 164	Nosocomial Infection N = 90	p-value
Pneumonia/bronchiolitis	46 (28%)	23 (26%)	0.67
Seizure	14 (9%)	9 (10%)	0.70
Sepsis	22 (13%)	8 (9%)	0.29
Shock	18 (11%)	6 (7%)	0.26
Trauma	32 (20%)	29 (32%)	0.02
Other	75 (46%)	47 (52%)	0.32
Chronic Diagnoses	78 (48%)	38 (42%)	0.41

Table 3

Multivariate logistic regression results for nosocomial infection admission risk factors

Variable	Adjusted Odds Ratio (95% Confidence Intervals)	P-value
Age (per one-year increase)	1.06 (1.01, 1.12)	0.03
Cardiac arrest (primary or secondary diagnosis) vs. No Cardiac arrest	6.74 (1.62, 28.08)	0.01
Lymphopenia (ALC $\leq$ 1,000 mm ³) vs. no Lymphopenia	2.03 (1.10, 3.76)	0.02
Trauma (primary or secondary diagnosis) vs. No Trauma	1.91 (0.96, 3.79)	0.07